Gjertsen, B T
Schöffski, P
Article History
Received: 19 February 2014
Revised: 5 June 2014
Accepted: 2 July 2014
First Online: 16 July 2014
Competing interests
: BG has received compensation as a member of the scientific advisory board of Clavis Pharma AS (2012), BerGenBio AS and Boehringer Ingelheim GmbH and owns shares in Kinn Therapeutics AS and Alden Cancer Therapy AS. PS declares no conflict of interest.